Oracle and AstraZeneca are working together to find out how artificial intelligence and health data can help connect research with patient care. This effort starts with a project focused on blood pressure in Abu Dhabi.
The partnership was announced on October 20 2026. It brings together AstraZeneca’s knowledge of drug development and clinical research with Oracle Health and Life Sciences’ cloud infrastructure, data abilities and AI tools. The companies have signed an agreement to study uses of these technologies not to create a full system right away.
Their goal is to solve problems in healthcare research. These problems include finding the right people to join trials creating proof from regular medical care and tracking medicines for safety issues.
Why finding people for trials is important
It is hard to find and get people to join clinical trials. Researchers need to find people who fit the study’s requirements check if they are eligible and get their agreement to take part. Delays at these steps can make studies more difficult. Cost more.
The new partnership will look into whether AI tools and health data can help find people who might be good for a trial. By making this information available in the ways doctors work the companies hope to make it easier for research opportunities to be found without removing the need for professional checks before someone joins.
A match found by software does not mean someone is automatically eligible. Doctors still need to check each person against the study’s rules. Participation also needs the permission and protection.
The partnership also wants to see how findings from research can help care. It also wants to look at how information collected during care can help with research questions. This is seen as a way to make sure scientific findings are connected to life medical work.
The first project is in Abu Dhabi
The first project will be based in Abu Dhabi and involve M42, a healthcare group that has services, technology and genomic abilities.
The companies plan to look into how AI tools can help doctors find people with blood pressure that is not under control. They also want to support care and check if these people might be good for clinical studies.
High blood pressure is a risk for heart disease, stroke and kidney problems. Many people may need checks or changes to their treatment. Finding these people early and giving them care is very important.
The project is meant to look at how information in the healthcare system can help doctors spot patients who need more checks. It is not saying that AI will diagnose blood pressure or give treatment on its own.
M42 said that medical supervision, privacy and managing data will be very important. People involved in research will still need to be checked by trained professionals and taking part will follow approved rules and get permission.
The Abu Dhabi project is part of a plan to build digital health systems in the United Arab Emirates. M42 and Oracle had already said they would bring together genetic and real-life health data using Oracle Health tools. This would create a base for work with data-based healthcare.
More projects in areas of disease
The global partnership is expected to look into uses in several of AstraZeneca’s areas of medicine. These areas include cancer, heart disease, kidney and metabolism issues, lung problems, immune system diseases and rare diseases.
Possible uses include matching people to trials finding disease earlier checking medicines for safety and using real-world evidence throughout the life of a medicine.
Real-world data is information collected during healthcare not just in trials. When properly handled and looked at this data can help researchers look at how treatments work in groups of patients.
These data sets have limits. Records may not be complete the people studied may not be all patients. What is seen in observations may not mean one thing causes another. Any results that help with choices need proper checking and control.
The companies said the work could happen in the US, the Middle East and Europe depending on rules. The announcement did not say how money the deal is worth or when the full plan will start.
Privacy and medical supervision are still key
Using health data for AI research brings up questions about keeping information safe who can see it and who is in charge. Medical records have details and using data between organizations or countries needs clear rules.
The companies say their work will follow rules and the protections set up by the healthcare systems involved. M42 also said doctors will still be in charge of decisions that affect patients.
These protections are very important when software finds someone who might be a fit for research. The system should not be used of a doctor’s check. A possible match should not be seen as a promise to get into a trial or get treatment.
The success of the program will depend on how the technology works in real medical situations if it helps research and if the benefits are worth the work and rules needed.
What this partnership means for AI in healthcare
The deal shows an effort to use AI in areas beyond simple digital assistants and into specific healthcare work. Drug companies are looking for ways to make research faster. Technology companies are trying to make their cloud, data and AI tools more useful in industries.
For Oracle the partnership is another chance to connect its healthcare tools with drug research. For AstraZeneca it offers a way to test if data-based medical steps can help find the people for studies and bring proof into care better. M42 gives a health partner for the first project in Abu Dhabi.
For now the announcement is the start of an experiment, not a big success. The next important steps will be to carry out projects show they help find people or work better and report clearly on patient protection and real results.
If this way works it could be a model for teamwork, between doctors, drug researchers and technology companies. Whether that helps make trials faster. Care better will depend on what comes next.
Nexuswild welcomes factual corrections. Email contact@nexuswild.com with evidence and the article URL.
